The first is a randomized phase II/III trial based on the results of PEMBRO-RT study [14] evaluating the anti-tumor activity of systemic immuno- or chemo-immunotherapy in patients with stage IV PD-L1 negative NSCLC. This evidence concerns the gene CD274 and neoplasm.